Side-by-side · Research reference

PancragenvsVesugen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED23/39 cited

BAnimal-MechanisticHUMAN-REVIEWED5/43 cited

Pancragen

Bioregulatory Tetrapeptide · Khavinson School

50 μgPrimate doseGoncharova 2014

10 daysTreatment cycleGoncharova 2015

3+ weeksEffect persistenceGoncharova 2014

IM · 10-day cycleGoncharova 2014

Vesugen

Bioregulatory Tripeptide · Vascular Endothelium

3 AATripeptide

Endothelin-1 ↓Atherosclerotic tissue

Ki-67 ↑Aged endothelium

SQ / IM · Protocol varies

01Mechanism of Action

Parameter

Pancragen

Vesugen

Primary target

Pancreatic acinar and islet cell differentiation pathwaysKhavinson 2013

Vascular endothelial cell nucleus — MKI67 gene promoter

Pathway

Transcription factor activation → Pdx1/Pax6/Pax4/Ptf1a/Foxa2/NKx2.2 upregulation → Cell differentiationKhavinson 2013

KED → MKI67 promoter interaction (CATC binding motif -14 to +12 bp) → Ki-67 proliferation protein ↑

Downstream effect

Enhanced pancreatic beta-cell function, normalized insulin/C-peptide dynamics, improved glucose clearanceGoncharova 2014

Normalised endothelin-1 expression in atherosclerotic/restenotic endothelium, restored connexin expression for cell-cell communication, enhanced proliferative capacity in senescent endothelial culturesKozlov 2016 Khavinson 2014

Feedback intact?

Yes — preserves physiological glucose-insulin response

Not applicable — does not operate via hormone axis

Origin

Synthetic tetrapeptide derived from pancreatic tissue extracts (Khavinson bioregulator methodology)

Khavinson bioregulatory peptide school — designed as tissue-specific (vascular) cytomodulator

Antibody development

—

02Dosage Protocols

Parameter

Pancragen

Vesugen

Primate dose (rhesus macaque)

50 μg / animal / dayGoncharova 2014

20–25-year-old females, 10-day IM protocol.

—

Effective concentration (in vitro)

0.05 ng/mLZakutskiĭ 2006

Organotypic tissue culture, both young and aged rat explants.

—

Route

IntramuscularGoncharova 2015

Subcutaneous or intramuscular

Frequency

Once daily for 10 daysGoncharova 2014

Not specified in available literature

Treatment cycle

10-day course, effects persist 3+ weeks post-withdrawalGoncharova 2014

—

Evidence basis

Non-human primate RCT, in vitro cell cultureGoncharova 2015 Khavinson 2013

Animal models (atherosclerosis, restenosis, aging) · Russian case series

Diabetes model

STZ-induced diabetes (rat)

Evaluated via metabolic markers characterizing apoptosis.

—

Standard dose (reported)

—

Not standardised — Russian clinical case series

Protocols vary; no FDA-approved regimen.

Duration

—

Case series report treatment courses in elderly arterial insufficiency

Half-life

—

Not reported

Tripeptides typically cleared rapidly.

04Side Effects & Safety

Parameter

Pancragen

Vesugen

Reported adverse events

None documented in primate studies

None documented in available abstracts

Tolerability

Well-tolerated in aged rhesus monkeys (n=9)Goncharova 2015

—

Human safety data

No published human trials; clinical use limited to Russian gerontology protocols

—

Injection site

—

Assumed minimal — typical for small peptides

Long-term safety

—

Unknown — no long-term RCT data

Epigenetic mechanism risk

—

Theoretical concern: direct gene promoter interaction — proliferative effects in non-target tissues not characterised

Absolute Contraindications

Pancragen

—

Vesugen

—

Relative Contraindications

Pancragen

·Active pancreatic malignancy (proliferation marker upregulation)

Vesugen

·Active malignancy — proliferative mechanism (Ki-67 upregulation) untested in oncologic context

05Administration Protocol

Parameter

Pancragen

Vesugen

1. Reconstitution

Lyophilised tetrapeptide reconstituted in sterile saline or water per manufacturer protocol. Concentration not specified in literature.

Lyophilised powder reconstituted with sterile water or bacteriostatic water per supplier protocol. No standardised formulation.

2. Route

Intramuscular injection. Primate studies used daily IM dosing for 10 consecutive days.Goncharova 2015

Subcutaneous (abdomen, thigh) or intramuscular. Rotate sites if multi-dose protocol.

3. Timing

No specific timing constraints documented. Administered once daily in primate protocols.

No reported circadian or fasting requirement. Russian protocols typically integrated into geroprotective regimens.

4. Cycle structure

10-day treatment course. Restorative effects on pancreatic function persist for at least 3 weeks post-discontinuation.Goncharova 2014

Lyophilised: refrigerate 2–8 °C, light-protected. Reconstituted: use immediately or refrigerate per supplier guidance (typically <7 days).

06Stack Synergy

Pancragen

— no documented stacks

Vesugen

+ Thymalin

Multi-pathway

View Thymalin →

Both from Khavinson bioregulatory school. Thymalin targets thymic/immune axis, Vesugen targets vascular endothelium. Rationale: multi-system geroprotection in elderly — immune senescence + vascular aging. Documented in Khavinson-tradition protocols combining tissue-specific peptides for poly-organ rejuvenation. No direct synergy study; combinatorial logic based on distinct target tissues.

Vesugen: Per protocol (SQ/IM)
Thymalin: Per protocol (SQ/IM)
Frequency: Sequential or concurrent per geroprotective protocol
Primary benefit: Multi-system age-related decline mitigation (vascular + immune)